You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥-B(02552.HK)宣佈華堂寧®商業化過渡,開啟新市場戰略
格隆匯 11-22 07:40

格隆匯11月22日丨華領醫藥-B(02552.HK)發佈公吿,2024年11月21日,其全資附屬公司華領醫藥技術(上海)有限公司(“華領上海”)向拜耳醫藥保健有限公司(“拜耳”)發出書面通知,表示有意自2025年1月1日起,將公司開發用於治療2型糖尿病的首創葡萄糖激酶激活劑華堂®(dorzagliatin片劑)在中國的商業化責任過渡至公司。

於2020年8月17日,有關各方就華堂寧®在中國的商業化建立合作關係並訂立相關的獨家推廣服務協議。根據協議,拜耳獲得華堂寧®於中國的獨家商業化權。自拜耳合作以來,已達成數個與華堂寧®相關的里程碑。該等里程碑包括:華堂寧®於2022年10月獲中國國家醫藥品監督管理局批准在中國銷售;其自 2024年1月1日起納入國家醫保藥品目錄(NRDL);截至本公吿日期,其已進入中國2000多家醫院;及其最近被中華醫學會糖尿病學分會納入《中國糖尿病防治指南(2024版)》。

為實現過渡,公司有權並計劃自2025年1月1日起終止協議。自本公吿日期起至終止生效日期止,拜耳與公司將繼續履行協議項下的義務並承諾啟動一個友好的、以患者為中心的過渡計劃。為支持華堂寧®在中國的持續商業銷售,公司可能會尋求其他潛在合作伙伴,以在中國進行華堂寧®的商業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account